A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19

Viruses
Nanomedicine
/References

Idris, Adi, Alicia Davis, Aroon Supramaniam, Dhruba Acharya, Gabrielle Kelly, Yaman Tayyar, Nic West, et al. 2021. “A SARS-CoV-2 Targeted SiRNA-Nanoparticle Therapy for COVID-19.” Molecular Therapy, May. https://doi.org/10.1016/j.ymthe.2021.05.004.

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans. Despite several emerging vaccines, there remains no verifiable therapeutic targeted specifically to the virus. Here we present a highly effective small interfering RNA (siRNA) therapeutic against SARS-CoV-2 infection using a novel lipid nanoparticle (LNP) delivery system. Multiple siRNAs targeting highly conserved regions of the SARS-CoV2 virus were screened, and three candidate siRNAs emerged that effectively inhibit the virus by greater than 90% either alone or in combination with one another. We simultaneously developed and screened two novel LNP formulations for the delivery of these candidate siRNA therapeutics to the lungs, an organ that incurs immense damage during SARS-CoV-2 infection. Encapsulation of siRNAs in these LNPs followed by in vivo injection demonstrated robust repression of virus in the lungs and a pronounced survival advantage to the treated mice. Our LNP-siRNA approaches are scalable and can be administered upon the first sign of SARS-CoV-2 infection in humans. We suggest that an siRNA-LNP therapeutic approach could prove highly useful in treating COVID-19 disease as an adjunctive therapy to current vaccine strategies.

View full article

Recent Publications

Surfactant-shell lipid nanocapsules (LNCs) are promising skin delivery systems. They are composed of an oily core with a stabilising shell of surfactant and phosphatidylcholine. LNCs’ hydrodynamic diameter can be easily tuned by varying the surfactant content in the formulation. Hydrophilic surfactants incorporated into LNCs have shown toxicity in mammalian cells. To date, the toxicity of all published surfactant-shelled LNCs produced by the the phase inverson temperature (PIT) method has been investigated using hydrophilic surfactants, with no studies examining the impact of incorporating hydrophobic surfactants on LNCs’ in vitro behaviour. Span 80 is a hydrophobic surfactant and has been extensively used in manufacturing various ranges of nanoparticles. The present study formulated Span 80-containing LNCs to evaluate their in vitro behaviour in the B16F10 melanoma cell line. LNC-100-S8 of Kolliphor HS15/Span 80 (65/35 w/w%) and original LNC100-0 LNCs of Kolliphor HS15 with a hydrodynamic diameter of 100 nm were prepared using the PIT method. A salt aggregation test confirmed increased surface hydrophobicity of LNC100-S8 compared to LNC100-0. Cytotoxicity assays demonstrated that LNC100-S8 had a three-fold lower cytotoxicity than LNC100-0 (IC80 = 11757 μg/mL vs 3184 μg/mL). Flow cytometry analysis indicated significantly higher cellular uptake of LNC100-S8 compared to LNC100-0, with 1.52-fold, 1.46-fold, and 1.67-fold increase at 1 h, 3 h, and 24 h, respectively . Mechanistic investigations revealed that LNC100-S8 uptake predominantly occured via phosphoinositide 3-kinase (PI3K)-regulated macropinocytosis and actin-dependent endocytosis, whereas LNC100-0 also utilised Na+/H+ exchanger-mediated macropinocytosis. Furthermore, protein corona analysis demonstrated increased interactions between LNC100-S8 and B16F10-conditioned media proteins, leading to bimodal size distribution and elevated polydispersity index (>0.3), which influenced their endocytic pathways. Overall, Our findings revealed the high promise of our Span 80-containing LNCs as a drug delivery system with enhanced cellular uptake and biocompatibility in B16F10 melanoma cells compared to conventional LNCs composed of Kolliphor HS15 surfactant, highlighting their potential uses in topical delivery to melanoma and other skin diseases.

2025
No items found.